Here you can find a selection of papers, articles and publications concerning Triveritas.
Tribune – the newsletter from Triveritas
Publications – papers we have written for industrial publication
The company spent a lot of time last year growing its presence in the North American clinical development market.
Triveritas is attempting to bring its expertise in regulatory, clinical, chemistry and manufacturing controls, toxicology, biologicals, pharmacovigilance and quality assurance to a broader client base.
Triveritas is the only animal health CRO located in the EU and the US with “the presence and expertise to develop veterinary medicinal products for both markets”. During the year, the company worked on over 170 new projects and enquiries across a host of companion animal and food-producing species.
Triveritas increased its customer base by more than 25% in 2017 to just under 100 clients. Currently, the firm has active projects for clients based in Australia, Belgium, Brazil, Canada, Chile, Germany, Ireland, Spain, Finland, France, Hungary, Israel, Italy, Japan, Netherlands, Norway, Sweden, Switzerland, Turkey, South Korea, the UK and the US. Importantly, its clients have a re-order rate of more than 95%.
Over the course of 2017, Triveritas also delivered training to more than 200 individuals in the areas of good clinical practice, vaccine development, companion animal medicines and regulatory affairs. Interestingly, Triveritas doubled its transatlantic studies conducted under a single protocol and worked on studies in some crucial next-generation areas of animal health such as monoclonal antibodies and non-surgical treatments for surface cancers on companion animals.